BIO tax reform lobbying to include net operating loss provisions.
BIO TAX REFORM LOBBYING WILL ADDRESS NOL CARRY-FORWARDS under Sec. 382 of the tax code, Biotechnology Industry Organization VP- Government Relations Chuck Ludlam said during a presentation on biotechnology tax issues in Washington, D.C. April 9. BIO is studying the change of ownership rule in Sec. 382, which requires a company that changes over 50% of its shareholders to amortize its net operating loss carry-forwards.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth